Dysfunction of the TP53 tumor suppressor gene in lymphoid malignancies

Blood

Volumn 119, Issue 16, 2012, Pages 3668-3683

  Xu Monette, Zijun Y ^a   Jeffrey Medeiros, L ^a   Li, Yong ^b   Orlowski, Robert Z ^c   Andreeff, Michael ^a   Bueso Ramos, Carlos E ^a   Greiner, Timothy C ^d   McDonnell, Timothy J ^a   Young, Ken H ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b University of Louisville School of Medicine   (United States)

^c Departments of Lymphoma and Myeloma   (United States)

^d UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CASPASE 3; CASPASE 9; MAMMALIAN TARGET OF RAPAMYCIN; MESSENGER RNA; MICRORNA; PROTEIN MDM2; PROTEIN P53;

ANGIOIMMUNOBLASTIC LYMPHADENOPATHY; APOPTOSIS; AUTOPHAGY; B CELL LYMPHOMA; BURKITT LYMPHOMA; CANCER INHIBITION; CARCINOGENESIS; CELL CYCLE ARREST; CELL NUCLEUS; CHRONIC LYMPHATIC LEUKEMIA; CYTOPLASM; DNA METHYLATION; DNA POLYMORPHISM; DNA REPAIR; EXON; FOLLICULAR LYMPHOMA; GENE EXPRESSION; GENE INACTIVATION; GENE MUTATION; GENETIC TRANSCRIPTION; HAIRY CELL LEUKEMIA; HODGKIN DISEASE; HUMAN; LARGE CELL LYMPHOMA; LARGE GRANULAR LYMPHOCYTE LEUKEMIA; LOSS OF FUNCTION MUTATION; LYMPHOCYTE; LYMPHOMA; MANTLE CELL LYMPHOMA; MARGINAL ZONE LYMPHOMA; MOLECULAR MECHANICS; MULTIPLE MYELOMA; PLASMA CELL LEUKEMIA; PRIMARY EFFUSION LYMPHOMA; PRIORITY JOURNAL; PROGNOSIS; PROLYMPHOCYTIC LEUKEMIA; PROTEIN DEGRADATION; PROTEIN FUNCTION; PROTEIN STRUCTURE; REVIEW; RNA STABILITY; RNA TRANSLATION; SENESCENCE; TRANSACTIVATION; TUMOR SUPPRESSOR GENE;

EID: 84860329005     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2011-11-366062     Document Type: Review

References (136)

1. Lane DP. Cancer: p53, guardian of the genome. Nature. 1992;358(6381):15-16.
2. Levine AJ. Introduction: the changing directions of p53 research. Genes Cancer. 2011;2(4):382-384.
3. Dai C, Gu W. p53 post-translational modification: deregulated in tumorigenesis. Trends Mol Med. 2010;16(11):528-536.
4. Boehme KA, Blattner C. Regulation of p53: insights into a complex process. Crit Rev Biochem Mol Biol. 2009;44(6):367-392.
5. Gaidarenko O, Xu Y. Transcription activity is required for p53-dependent tumor suppression. On-cogene. 2009;28(49):4397-4401.
6. Zschenker O, Borgmann K, Streichert T, Meier I, Wrona A, Dikomey E. Lymphoblastoid cell lines differing in p53 status show clear differences in basal gene expression with minor changes after irradiation. Radiother Oncol. 2006;80(2):236-249. (Pubitemid 44314016)
7. Tsai MH, Chen X, Chandramouli GV, et al. Tran-scriptional responses to ionizing radiation reveal that p53R2 protects against radiation-induced mutagenesis in human lymphoblastoid cells. Oncogene. 2006;25(4):622-632. (Pubitemid 43164472)
8. Robles AI, Bemmels NA, Foraker AB, Harris CC. APAF-1 is a transcriptional target of p53 in DNA damage-induced apoptosis. Cancer Res. 2001; 61(18):6660-6664. (Pubitemid 32896481)
9. Akerman GS, Rosenzweig BA, Domon OE, et al. Alterations in gene expression profiles and the DNA-damage response in ionizing radiation-exposed TK6 cells. Environ Mol Mutagen. 2005; 45(2):188-205.
10. Kannan K, Kaminski N, Rechavi G, Jakob-Hirsch J, Amariglio N, Givol D. DNA microarray analysis of genes involved in p53 mediated apoptosis: activation of Apaf-1. Oncogene. 2001;20(26): 3449-3455. (Pubitemid 32588994)
11. Amundson SA, Do KT, Vinikoor LC, et al. Integrating global gene expression and radiation survival parameters across the 60 cell lines of the National Cancer Institute Anticancer Drug Screen. Cancer Res. 2008;68(2):415-424. (Pubitemid 351380067)
12. Talos F, Petrenko O, Mena P, Moll UM. Mitochon-drially targeted p53 has tumor suppressor activities in vivo. Cancer Res. 2005;65(21):9971-9981. (Pubitemid 41541478)
13. Armstrong JS, Steinauer KK, Hornung B, et al. Role of glutathione depletion and reactive oxygen species generation in apoptotic signaling in a human B lymphoma cell line. Cell Death Differ. 2002;9(3):252-263. (Pubitemid 34223869)
14. Hollstein M, Hainaut P. Massively regulated genes: the example of TP53. J Pathol. 2010; 220(2):164-173.
15. Chen S, Rehman SK, Zhang W, Wen A, Yao L, Zhang J. Autophagy is a therapeutic target in anti-cancer drug resistance. Biochim Biophys Acta. 2010;1806(2):220-229.
16. Amrein L, Soulieres D, Johnston JB, Aloyz R. p53 and autophagy contribute to dasatinib resistance in primary CLL lymphocytes. Leuk Res. 2011; 35(1):99-102.
17. Griffiths-Jones S. miRBase: microRNA sequences and annotation. Curr Protoc Bioinformatics. 2010; Chapter 12:Unit 10.
18. Fabbri M, Bottoni A, Shimizu M, et al. Association of a microRNA/TP53 feedback circuitry with pathogenesis and outcome of B-cell chronic lym-phocytic leukemia. JAMA. 2011;305(1):59-67.
19. Rao DS, O'Connell RM, Chaudhuri AA, Garcia-Flores Y, Geiger TL, Baltimore D. MicroRNA-34a perturbs B lymphocyte development by repressing the forkhead box transcription factor Foxp1. Immunity. 2010;33(1):48-59.
20. Calin GA, Dumitru CD, Shimizu M, et al. Frequent deletions and down-regulation of micro-RNA genes miR15 and miR16 at 13q14 in chronic lym-phocytic leukemia. Proc Natl Acad Sci U S A. 2002;99(24):15524-15529. (Pubitemid 35403967)
21. Merkel O, Asslaber D, Pinon JD, Egle A, Greil R. Interdependent regulation of p53 and miR-34a in chronic lymphocytic leukemia. Cell Cycle. 2010; 9(14):2764-2768.
22. Boominathan L. The guardians of the genome (p53, TA-p73, and TA-p63) are regulators of tumor suppressor miRNAs network. Cancer Metastasis Rev. 2010;29(4):613-639.
23. Roehle A, Hoefig KP, Repsilber D, et al. MicroRNA signatures characterize diffuse large B-cell lymphomas and follicular lymphomas. Br J Haematol. 2008;142(5):732-744.
24. Chaudhry MA, Kreger B, Omaruddin RA. Tran-scriptional modulation of micro-RNA in human cells differing in radiation sensitivity. Int J Radiat Biol. 2010;86(7):569-583.
25. Lagos-Quintana M, Rauhut R, Yalcin A, Meyer J, Lendeckel W, Tuschl T. Identification of tissue-specific microRNAs from mouse. Curr Biol. 2002; 12(9):735-739. (Pubitemid 34455427)
26. Robbiani DF, Bunting S, Feldhahn N, et al. AID produces DNA double-strand breaks in non-Ig genes and mature B cell lymphomas with reciprocal chromosome translocations. Mol Cell. 2009; 36(4):631-641.
27. Yan HL, Xue G, Mei Q, et al. Repression of the miR-17-92 cluster by p53 has an important function in hypoxia-induced apoptosis. EMBO J. 2009;28(18):2719-2732.
28. Pichiorri F, Suh SS, Rocci A, et al. Downregulation of p53-inducible microRNAs 192, 194, and 215 impairs the p53/MDM2 autoregulatory loop in multiple myeloma development. Cancer Cell. 2010;18(4):367-381.
29. Marton S, Garcia MR, Robello C, et al. Small RNAs analysis in CLL reveals a deregulation of miRNA expression and novel miRNA candidates of putative relevance in CLL pathogenesis. Leukemia. 2008;22(2):330-338. (Pubitemid 351250538)
30. Mraz M, Pospisilova S, Malinova K, Slapak I, Mayer J. MicroRNAs in chronic lymphocytic leukemia pathogenesis and disease subtypes. Leuk Lymphoma. 2009;50(3):506-509.
31. Ji M, Rao E, Ramachandrareddy H, et al. The miR-17-92 microRNA cluster is regulated by multiple mechanisms in B-cell malignancies. Am J Pathol. 2011;179(4):1645-1656.
32. Yamanaka Y, Tagawa H, Takahashi N, et al. Aberrant overexpression of microRNAs activate AKT signaling via down-regulation of tumor suppressors in natural killer-cell lymphoma/leukemia. Blood. 2009;114(15):3265-3275.
33. Lu LF, Thai TH, Calado DP, et al. Foxp3-dependent microRNA155 confers competitive fitness to regulatory T cells by targeting SOCS1 protein. Immunity. 2009;30(1):80-91.
34. Lawrie CH, Chi J, Taylor S, et al. Expression of microRNAs in diffuse large B cell lymphoma is associated with immunophenotype, survival and transformation from follicular lymphoma. J Cell Mol Med. 2009;13(7):1248-1260.
35. Akao Y, Nakagawa Y, Kitade Y, Kinoshita T, Naoe T. Downregulation of microRNAs-143 and -145 in B-cell malignancies. Cancer Sci. 2007;98(12): 1914-1920. (Pubitemid 350002197)
36. Vousden KH, Lu X. Live or let die: the cell's response to p53. Nat Rev Cancer. 2002;2(8):594-604. (Pubitemid 37328926)
37. Gudkov AV, Komarova EA. The role of p53 in determining sensitivity to radiotherapy. Nat Rev Cancer. 2003;3(2):117-129. (Pubitemid 37328879)
38. Kojima K, Shimanuki M, Shikami M, Andreeff M, Nakakuma H. Cyclin-dependent kinase 1 inhibitor RO-3306 enhances p53-mediated Bax activation and mitochondrial apoptosis in AML. Cancer Sci. 2009;100(6):1128-1136.
39. Schmitt CA, Fridman JS, Yang M, et al. A senescence program controlled by p53 and p16INK4a contributes to the outcome of cancer therapy. Cell. 2002;109(3):335-346. (Pubitemid 34606876)
40. Post SM, Quintas-Cardama A, Terzian T, Smith C, Eischen CM, Lozano G. p53-dependent senescence delays Emu-myc-induced B-cell lymphom-agenesis. Oncogene. 2010;29(9):1260-1269.
41. Feldser DM, Greider CW. Short telomeres limit tumor progression in vivo by inducing senescence. Cancer Cell. 2007;11(5):461-469. (Pubitemid 46670077)
42. Amaravadi RK, Yu D, Lum JJ, et al. Autophagy inhibition enhances therapy-induced apoptosis in a Myc-induced model of lymphoma. J Clin Invest. 2007;117(2):326-336. (Pubitemid 46203961)
43. Carew JS, Nawrocki ST, Kahue CN, et al. Targeting autophagy augments the anticancer activity of the histone deacetylase inhibitor SAHA to overcome Bcr-Abl-mediated drug resistance. Blood. 2007;110(1):313-322. (Pubitemid 47026849)
44. Hoang B, Benavides A, Shi Y, Frost P, Lichtenstein A. Effect of autophagy on multiple myeloma cell viability. Mol Cancer Ther. 2009; 8(7):1974-1984.
45. Harvey M, McArthur MJ, Montgomery CA Jr, Bradley A, Donehower LA. Genetic background alters the spectrum of tumors that develop in p53-deficient mice. FASEB J. 1993;7(10):938-943. (Pubitemid 23225552)
46. Donehower LA, Harvey M, Slagle BL, et al. Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumours. Nature. 1992;356(6366):215-221.
47. Jacks T, Remington L, Williams BO, et al. Tumor spectrum analysis in p53-mutant mice. Curr Biol. 1994;4(1):1-7.
48. MacPherson D, Kim JH, Kim T, et al. Defective apoptosis and B-cell lymphomas in mice with p53 point mutation at Ser 23. EMBO J. 2004;23(18): 3689-3699. (Pubitemid 39336290)
49. Armata HL, Garlick DS, Sluss HK. The ataxia telangiectasia-mutated target site Ser(18) is required for p53-mediated tumor suppression. Cancer Res. 2007;67(24):11696-11703.
50. Schmitt CA, Fridman JS, Yang M, Baranov E, Hoffman RM, Lowe SW. Dissecting p53 tumor suppressor functions in vivo. Cancer Cell. 2002; 1(3):289-298. (Pubitemid 41039153)
51. Peller S, Rotter V. TP53 in hematological cancer: low incidence of mutations with significant clinical relevance. Hum Mutat. 2003;21(3):277-284. (Pubitemid 36292969)
52. Mestre-Escorihuela C, Rubio-Moscardo F, Richter JA, et al. Homozygous deletions localize novel tumor suppressor genes in B-cell lympho-mas. Blood. 2007;109(1):271-280. (Pubitemid 46053067)
53. Petitjean A, Mathe E, Kato S, et al. Impact of mutant p53 functional properties on TP53 mutation patterns and tumor phenotype: lessons from recent developments in the IARC TP53 database. Hum Mutat. 2007;28(6):622-629. (Pubitemid 46744292)
54. Kato S, Han SY, Liu W, et al. Understanding the function-structure and function-mutation relationships of p53 tumor suppressor protein by high-resolution missense mutation analysis. Proc Natl Acad Sci U S A. 2003;100(14):8424-8429. (Pubitemid 36842561)
55. Rivlin N, Brosh R, Oren M, Rotter V. Mutations in the p53 tumor suppressor gene: important milestones at the various steps of tumorigenesis. Genes Cancer. 2011;2(4):466-474.
56. Wang F, Liu J, Robbins D, et al. Mutant p53 exhibits trivial effects on mitochondrial functions which can be reactivated by ellipticine in lym-phoma cells. Apoptosis. 2011;16(3):301-310.
57. Ahn BY, Trinh DL, Zajchowski LD, Lee B, Elwi AN, Kim SW. Tid1 is a new regulator of p53 mitochon-drial translocation and apoptosis in cancer. Onco-gene. 2010;29(8):1155-1166.
58. Petitjean A, Achatz MI, Borresen-Dale AL, Hainaut P, Olivier M. TP53 mutations in human cancers: functional selection and impact on cancer prognosis and outcomes. Oncogene. 2007; 26(15):2157-2165. (Pubitemid 46536647)
59. Joerger AC, Fersht AR. Structural biology of the tumor suppressor p53. Annu Rev Biochem. 2008; 77:557-582.
60. Chan WJ. Pathogenesis of diffuse large B cell lymphoma. Int J Hematol. 2010;92(2):219-230.
61. Sturm I, Bosanquet AG, Hermann S, Guner D, Dorken B, Daniel PT. Mutation of p53 and consecutive selective drug resistance in B-CLL occurs as a consequence of prior DNA-damaging chemotherapy. Cell Death Differ. 2003;10(4):477-484. (Pubitemid 36626360)
62. Pekova S, Mazal O, Cmejla R, et al. Acompre-hensive study of TP53 mutations in chronic lym-phocytic leukemia: analysis of 1287 diagnostic and 1148 follow-up CLL samples. Leuk Res. 2011;35(7):889-898.
63. Whibley C, Pharoah PD, Hollstein M. p53 polymorphisms: cancer implications. Nat Rev Cancer. 2009;9(2):95-107.
64. Agirre X, Novo FJ, Calasanz MJ, et al. TP53 is frequently altered by methylation, mutation, and/or deletion in acute lymphoblastic leukaemia. Mol Carcinog. 2003;38(4):201-208. (Pubitemid 37523712)
65. Hishida A, Matsuo K, Tajima K, et al. Polymorphisms of p53 Arg72Pro, p73 G4C14-to-A4T14 at exon 2 and p21 Ser31Arg and the risk of non-Hodgkin's lymphoma in Japanese. Leuk Lym-phoma. 2004;45(5):957-964. (Pubitemid 38444672)
66. Takeuchi S, Matsushita M, Tsukasaki K, et al. P53 codon 72 polymorphism is associated with disease progression in adult T-cell leukaemia/lymphoma. Br J Haematol. 2005;131(4):552-553. (Pubitemid 43899655)
67. Kim HN, Yu L, Kim NY, et al. Association with TP53 codon 72 polymorphism and the risk of non-Hodgkin lymphoma. Am J Hematol. 2010; 85(10):822-824.
68. Tuck SP, Crawford L. Characterization of the human p53 gene promoter. Mol Cell Biol. 1989; 9(5):2163-2172. (Pubitemid 19117817)
69. Bourdon JC. p53 and its isoforms in cancer. Br J Cancer. 2007;97(3):277-282.
70. Reisman D, Rotter V. Two promoters that map to 5'-sequences of the human p53 gene are differentially regulated during terminal differentiation of human myeloid leukemic cells. Oncogene. 1989; 4(8):945-953. (Pubitemid 19202809)
71. Attwooll CL, McGown G, Thorncroft M, Stewart FJ, Birch JM, Varley JM. Identification of a rare polymorphism in the human TP53 promoter. Cancer Genet Cytogenet. 2002;135(2):165-172. (Pubitemid 34786768)
72. Stuart ET, Haffner R, Oren M, Gruss P. Loss of p53 function through PAX-mediated transcriptional repression. EMBOJ. 1995;14(22):5638-5645.
73. Iida S, Rao PH, Nallasivam P, et al. The t(9; 14)(p13;q32) chromosomal translocation associated with lymphoplasmacytoid lymphoma involves the PAX-5 gene. Blood. 1996;88(11):4110-4117. (Pubitemid 26399155)
74. Basso K, Dalla-Favera R. BCL6: master regulator of the germinal center reaction and key oncogene in Bcell lymphomagenesis. AdvImmunol. 2010; 105:193-210.
75. Agirre X, Vizmanos JL, Calasanz MJ, Garcia-Delgado M, Larrayoz MJ, Novo FJ. Meth-ylation of CpG dinucleotides and/or CCWGG motifs at the promoter of TP53 correlates with decreased gene expression in a subset of acute lymphoblastic leukemia patients. Oncogene. 2003;22(7):1070-1072. (Pubitemid 36313150)
76. Valganon M, Giraldo P, Agirre X, et al. p53 aberrations do not predict individual response to fludarabine in patients with B-cell chronic lymphocytic leukaemia in advanced stages Rai III/IV. Br J Haematol. 2005;129(1):53-59. (Pubitemid 40524051)
77. Amara K, Trimeche M, Ziadi S, et al. Presence of simian virus 40 DNAsequences in diffuse large B-cell lymphomas in Tunisia correlates with aberrant promoter hypermethylation of multiple tumor suppressor genes. Int J Cancer. 2007;121(12): 2693-2702. (Pubitemid 350136414)
78. Bourdon JC, Fernandes K, Murray-Zmijewski F et al. p53 isoforms can regulate p53 transcriptional activity. Genes Dev. 2005;19(18):2122-2137. (Pubitemid 41330315)
79. Graupner V, Schulze-Osthoff K, Essmann F Janicke RU. Functional characterization of p53beta and p53gamma, two isoforms of the tumor suppressor p53. Cell Cycle. 2009;8(8):1238-1248.
80. Grover R, Candeias MM, Fahraeus R, Das S. p53 and little brother p53/47: linking IRES activities with protein functions. Oncogene. 2009;28(30): 2766-2772.
81. Yin Y, Stephen CW, Luciani MG, Fahraeus R. p53 Stability and activity is regulated by Mdm2-mediated induction of alternative p53 translation products. Nat Cell Biol. 2002;4(6):462-467. (Pubitemid 34746166)
82. Rohaly G, Chemnitz J, Dehde S, et al. A novel human p53 isoform is an essential element of the ATR-intra-S phase checkpoint. Cell. 2005;122(1): 21-32. (Pubitemid 40977937)
83. Pekova S, Cmejla R, Smolej L, Kozak T, Spacek M, Prucha M. Identification of a novel, transactivation-defective splicing variant of p53 gene in patients with chronic lymphocytic leukemia. Leuk Res. 2008;32(3):395-400. (Pubitemid 351295913)
84. Anensen N, Oyan AM, Bourdon JC, Kalland KH, Bruserud O, Gjertsen BT. A distinct p53 protein isoform signature reflects the onset of induction chemotherapy for acute myeloid leukemia. Clin Cancer Res. 2006;12(13):3985-3992. (Pubitemid 44078084)
85. Vilborg A, Wilhelm MT, Wiman KG. Regulation of tumor suppressor p53at the RNA level. JMol Med. 2010;88(7):645-652.
86. Nakamura H, Kawagishi H, Watanabe A, Sugimoto K, Maruyama M, Sugimoto M. Cooperative role of the RNA-binding proteins Hzf and HuR in p53 activation. Mol Cell Biol. 2011;31(10): 1997-2009.
87. Candeias MM, Malbert-Colas L, Powell DJ, et al. P53 mRNA controls p53 activity by managing Mdm2 functions. Nat Cell Biol. 2008;10(9):1098-1105.
88. Kumar M, Lu Z, Takwi AA, et al. Negative regulation of the tumor suppressor p53 gene by micro-RNAs. Oncogene. 2011;30(7):843-853.
89. Le MT, Teh C, Shyh-Chang N, et al. MicroRNA-125b is a novel negative regulator of p53. Genes Dev. 2009;23(7):862-876.
90. Malumbres R, Sarosiek KA, Cubedo E, et al. Differentiation stage-specific expression of microRNAs in B lymphocytes and diffuse large B-cell lymphomas. Blood. 2009;113(16):3754-3764.
91. Pichiorri F, Suh SS, Ladetto M, et al. MicroRNAs regulate critical genes associated with multiple myeloma pathogenesis. Proc Natl Acad Sci USA. 2008;105(35):12885-12890.
92. Hu W, Chan CS, Wu R, et al. Negative regulation of tumor suppressor p53 by microRNA miR-504. Mol Cell. 2010;38(5):689-699.
93. Tian S, Huang S, Wu S, Guo W, Li J, He X. MicroRNA-1285 inhibits the expression of p53 by directly targeting its 3' untranslated region. Biochem Biophys Res Commun. 2010;396(2): 435-439.
94. Neveu P, Kye MJ, Qi S, et al. MicroRNA profiling reveals two distinct p53-related human pluripo-tent stem cell states. Cell Stem Cell. 2010;7(6): 671-681.
95. He L, Thomson JM, Hemann MT, et al. A microRNA polycistron as a potential human oncogene. Nature. 2005;435(7043):828-833. (Pubitemid 40839734)
96. Enomoto Y, Kitaura J, Hatakeyama K, et al. Emu/miR-125b transgenic mice develop lethal B-cell malignancies. Leukemia. 2011;25(12): 1849-1856.
97. Lu X. p53: a heavily dictated dictator of life and death. CurrOpin Genet Dev. 2005;15(1):27-33. (Pubitemid 40127628)
98. Inoue T, Geyer RK, Howard D, Yu ZK, Maki CG. MDM2 can promote the ubiquitination, nuclear export, and degradation of p53 in the absence of direct binding. J Biol Chem. 2001;276(48):45255-45260.
99. Ghosh A, Stewart D, Matlashewski G. Regulation of human p53 activity and cell localization by alternative splicing. Mol Cell Biol. 2004;24(18): 7987-7997. (Pubitemid 39167449)
100. Toledo F, Wahl GM. Regulating the p53 pathway: in vitro hypotheses, in vivo veritas. Nat Rev Cancer. 2006;6(12):909-923. (Pubitemid 44862676)
101. Roberti A, Rizzolio F, Lucchetti C, de Leval L, Giordano A. Ubiquitin-mediated protein degradation and methylation-induced gene silencing cooperate in the inactivation of the INK4/ARF locus in Burkitt lymphoma cell lines. Cell Cycle. 2011; 10(1):127-134.
102. Kim DH, Kundu JK, Surh YJ. Redox modulation of p53: mechanisms and functional significance. Mol Carcinog. 2011;50(4):222-234.
103. Agirre X, Roman-Gomez J, Jimenez-Velasco A, et al. ASPP1, a common activator of TP53, is inactivated by aberrant methylation of its promoter in acute lymphoblastic leukemia. Oncogene. 2006;25(13):1862-1870.
104. Pettitt AR, Sherrington PD, Stewart G, Cawley JC, Taylor AM, Stankovic T p53 dysfunction in B-cell chronic lymphocytic leukemia: inactivation of ATM as an alternative to TP53 mutation. Blood. 2001; 98(3):814-822.
105. Kojima K, Konopleva M, McQueen T, O'Brien S, Plunkett W, Andreeff M. Mdm2 inhibitor Nutlin-3a induces p53-mediated apoptosis by transcription-dependent and transcription-independent mechanisms and may overcome Atm-mediated resistance to fludarabine in chronic lymphocytic leukemia. Blood. 2006;108(3):993-1000. (Pubitemid 44154636)
106. Coutts AS, Adams CJ, LaThangue NB. p53 ubiquitination by Mdm2: a never ending tail? DNA Repair (Amst). 2009;8(4):483-490.
107. Waster PK, Ollinger KM. Redox-dependent translocation of p53 to mitochondria or nucleus in human melanocytes after UVA- and UVB-induced apoptosis. J Invest Dermatol. 2009;129(7):1769-1781.
108. Pei XH, Bai F, Li Z, et al. Cytoplasmic CUL9/PARC ubiquitin ligase is a tumor suppressor and promotes p53-dependent apoptosis. Cancer Res. 2011;71(8):2969-2977.
109. Stoffel A, Levine AJ. Actvation of NF-kappaB by the API2/MALT1 fusions inhibits p53 dependant but not FAS induced apoptosis: a directional link between NF-kappaB and p53. Cell Cycle. 2004; 3(8):1017-1020. (Pubitemid 40268656)
110. Lotem J, Gal H, Kama R, et al. Inhibition of p53-induced apoptosis without affecting expression of p53-regulated genes. Proc Natl Acad Sci U S A. 2003;100(11):6718-6723. (Pubitemid 36666646)
111. Vesely DL, Hoffman B, Liebermann DA. Phosphatidylinositol 3-kinase/Akt signaling mediates interleukin-6 protection against p53-induced apoptosis in M1 myeloid leukemic cells. Oncogene. 2007;26(21):3041-3050. (Pubitemid 46733643)
112. Coloff JL, Mason EF, Altman BJ, et al. Akt requires glucose metabolism to suppress puma expression and prevent apoptosis of leukemic T cells. J Biol Chem. 2011;286(7):5921-5933.
113. Chipuk JE, Maurer U, Green DR, Schuler M. Pharmacologic activation of p53 elicits Bax-dependent apoptosis in the absence of transcription. Cancer Cell. 2003;4(5):371-381. (Pubitemid 37491098)
114. Cillessen SA, Meijer CJ, Notoya M, Ossenkoppele GJ, Oudejans JJ. Molecular targeted therapies for diffuse large B-cell lymphoma based on apoptosis profiles. J Pathol. 2010; 220(5):509-520.
115. Martins CP, Brown-Swigart L, Evan GI. Modeling the therapeutic efficacy of p53 restoration in tumors. Cell. 2006;127(7):1323-1334. (Pubitemid 44960417)
116. Terzian T, Wang Y, Van Pelt CS, Box NF Travis EL, Lozano G. Haploinsufficiency of Mdm2 and Mdm4 in tumorigenesis and development. Mol Cell Biol. 2007;27(15):5479-5485. (Pubitemid 47124400)
117. Abbas HA, Maccio DR, Coskun S, et al. Mdm2 is required for survival of hematopoietic stem cells/progenitors via dampening of ROS-induced p53 activity. Cell Stem Cell. 2010;7(5):606-617.
118. Kurland JF, Meyn RE. Protease inhibitors restore radiation-induced apoptosis to Bcl-2-expressing lymphoma cells. Int J Cancer. 2001;96(6):327-333. (Pubitemid 33136285)
119. Anshu A, Thomas S, Agarwal P, Ibarra-Rivera TR, Pirrung MC, Schonthal AH. Novel proteasome-inhibitory syrbactin analogs inducing endoplasmic reticulum stress and apoptosis in hematological tumor cell lines. Biochem Pharmacol. 2011;82(6): 600-609.
120. Fischer U, Janssen K, Schulze-Osthoff K. Cutting-edge apoptosis-based therapeutics: a panacea for cancer? BioDrugs. 2007;21(5):273-297. (Pubitemid 47529468)
121. Drakos E, Singh RR, Rassidakis GZ, et al. Activation of the p53 pathway by the MDM2 inhibitor nutlin-3a overcomes BCL2 overexpression in a preclinical model of diffuse large B-cell lymphoma associated with t(14;18)(q32;q21). Leukemia. 2011;25(5):856-867.
122. Drakos E, Atsaves V, Schlette E, et al. The therapeutic potential of p53 reactivation by nutlin-3a in ALK+ anaplastic large cell lymphoma with wild-type or mutated p53. Leukemia. 2009;23(12): 2290-2299.
123. Hayashi Y, Kondo T, Zhao QL, et al. Signal transduction of p53-independent apoptotic pathway induced by hexavalent chromium in U937 cells. Toxicol Appl Pharmacol. 2004;197(2):96-106. (Pubitemid 38639900)
124. Wilson HA, Allred DV, O'Neill K, Bell JD. Activities and interactions among phospholipases A2 during thapsigargin-induced S49 cell death. Apoptosis. 2000;5(4):389-396.
125. Balasubramanian S, Ramos J, Luo W, Sirisawad M, Verner E, Buggy JJ. A novel histone deacetylase 8 (HDAC8)-specific inhibitor PCI-34051 induces apoptosis in T-cell lymphomas. Leukemia. 2008; 22(5):1026-1034. (Pubitemid 351689885)
126. Danen-Van Oorschot AA, Van Der Eb AJ, Noteborn MH. BCL-2 stimulates Apoptin-induced apoptosis. Adv Exp Med Biol. 1999;457:245-249.
127. Ho SY, Chen WC, Chiu HW, Lai CS, Guo HR, Wang YJ. Combination treatment with arsenic trioxide and irradiation enhances apoptotic effects in U937 cells through increased mitotic arrest and ROS generation. Chem Biol Interact. 2009; 179(2):304-313.
128. Guo HR, Chen CH, Ho SY, Ho YS, Chen RJ, Wang YJ. Staurosporine modulates radiosensitivity and radiation-induced apoptosis in U937 cells. Int J Radiat Biol. 2006;82(2):97-109.
129. Paquet C, Schmitt E, Beauchemin M, Bertrand R. Activation of multidomain and BH3-only proapoptotic Bcl-2 family members in p53-defective cells. Apoptosis. 2004;9(6):815-831. (Pubitemid 40941210)
130. Alas S, Ng CP, Bonavida B. Rituximab modifies the cisplatin-mitochondrial signaling pathway, resulting in apoptosis in cisplatin-resistant non-Hodgkin's lymphoma. Clin Cancer Res. 2002; 8(3):836-845. (Pubitemid 34742116)
131. Tonino SH, van Laar J, van Oers MH, Wang JY, Eldering E, Kater AP. ROS-mediated upregulation of Noxa overcomes chemoresistance in chronic lymphocytic leukemia. Oncogene. 2011;30(6): 701-713.
132. Chitambar CR, Purpi DP, Woodliff J, Yang M, Wereley JP. Development of gallium compounds for treatment of lymphoma: gallium maltolate, a novel hydroxypyrone gallium compound, induces apoptosis and circumvents lymphoma cell resistance to gallium nitrate. J Pharmacol Exp Ther. 2007;322(3):1228-1236. (Pubitemid 47295794)
133. Gaikwad A, Poblenz A, Haridas V, Zhang C, Duvic M, Gutterman J. Triterpenoid electrophiles (avicins) suppress heat shock protein-70 and x-linked inhibitor of apoptosis proteins in malignant cells by activation of ubiquitin machinery: implications for proapoptotic activity. Clin Cancer Res. 2005;11(5):1953-1962. (Pubitemid 40471861)
134. Fingrut O, Reischer D, Rotem R, et al. Jasmonates induce nonapoptotic death in high-resistance mutant p53-expressing B-lymphoma cells. Br J Pharmacol. 2005;146(6):800-808. (Pubitemid 41622246)
135. Wong CH, Iskandar KB, Yadav SK, Hirpara JL, Loh T, Pervaiz S. Simultaneous induction of non-canonical autophagy and apoptosis in cancer cells by ROS-dependent ERK and JNK activation. PLoS One. 2010;5(4):e9996.
136. Bartel DP. MicroRNAs: target recognition and regulatory functions. Cell. 2009;136(2):215-233.